In a significant move within the healthtech sector, NEX Health Intelligence has successfully raised €1 million in a pre-seed funding round. Spearheaded by Brighteye Ventures, the round also saw participation from several other key investors, signaling substantial interest in NEX’s approach to healthcare-associated infections. These infections remain a critical issue affecting numerous patients, contributing to increased hospital stays and added healthcare costs. The fresh influx of capital aims to bolster NEX’s efforts in addressing this challenge through its innovative use of artificial intelligence.
NEX Health Intelligence stands out with its unique AI-driven infection intelligence platform, designed to predict and prevent infections before they have a chance to proliferate. The platform offers hospitals an early detection system for spotting transmission risks allowing earlier intervention with specific prevention measures. In recent years, the need for such smart technologies in healthcare has become evident, especially in high-stakes environments like hospitals where resistant infections can escalate quickly and cause operational challenges.
How did NEX Health Intelligence Begin?
The inception of NEX Health Intelligence stems from Dr. Ashleigh Myall’s experience working with the NHS during the COVID-19 pandemic. As he handled patient admissions, he noticed the rapid spread of infections among vulnerable individuals in hospitals.
While supporting the NHS COVID-19 response, I realised the real challenge wasn’t just the number of admissions – it was how quickly infections spread between vulnerable patients already inside hospitals,
reflected Dr. Myall, leading him to create predictive AI systems.
Where Does NEX Operate Now?
NEX’s operations currently span various healthcare facilities, both within the UK and internationally. The company collaborates with NHS organizations, with evaluation projects in two London NHS Trusts and implementations in North West England. Internationally, it operates in a military hospital in Southeast Asia and is actively expanding with ventures in Malaysia. Such efforts underline the global reach and applicability of their platform.
The latest financial backing will enable further expansion within the UK and beyond, and it aims to enhance regulatory and clinical safety standards. Additionally, the company seeks to generate more robust clinical and economic evidence from ongoing and future deployments. The €1 million boost underscores an emphasis on expanding the applicability and reach of NEX’s infection control solutions.
Recent product developments have led to notable improvements in compliance rates in infection control, supporting over 40,000 patient admissions globally. This success reinforces the platform’s potential impact on healthcare safety. Notably, NEX’s expanding ventures in international markets highlight its strategic approach to broadening the influence and adoption of its platform.
The focus on international projects, especially in Southeast Asia, demonstrates an understanding of diverse healthcare landscapes and the universal need for enhanced infection control. Securing this funding marks a crucial step in addressing the persistent issues of infections in hospitals and showcases the pivotal role of AI in modern healthcare.
The comparison of NEX Health Intelligence to similar initiatives reveals the company’s uniqueness in leveraging AI to tackle hospital infections. Unlike some solutions focusing solely on reactive measures, NEX’s predictive model aims to intervene before infections spread, offering a proactive stance in infection control. The funding underscores investor confidence in this methodology’s effectiveness and potential for widespread adoption.
